

# Société Générale

## Pan European Conference

June 4, 2013

**Pierre Kemula**  
Vice President, Corporate Finance, Treasury and Financial Markets



# Disclaimer

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners.

The implementation of the strategy has to be submitted to the relevant staff representation authorities in each country concerned, in compliance with the specific procedures, terms and conditions set forth by each national legislation.

# Safe Harbor

The Group operates in certain geographical regions whose governmental finances, local currencies or inflation rates could be affected by the current crisis, which could in turn erode the local competitiveness of the Group's products relative to competitors operating in local currency, and/or could be detrimental to the Group's margins in those regions where the Group's drugs are billed in local currencies.

In a number of countries, the Group markets its drugs via distributors or agents: some of these partners' financial strength could be impacted by the crisis, potentially subjecting the Group to difficulties in recovering its receivables. Furthermore, in certain countries whose financial equilibrium is threatened by the crisis and where the Group sells its drugs directly to hospitals, the Group could be forced to lengthen its payment terms or could experience difficulties in recovering its receivables in full.

Finally, in those countries in which public or private health cover is provided, the impact of the financial crisis could cause medical insurance agencies to place added pressure on drug prices, increase financial contributions by patients or adopt a more selective approach to reimbursement criteria.

All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today.

# Agenda

**1**

**2012, healthy performance in a challenging year**

**2**

**Business and strategy update**

**3**

**2013 financial objectives and closing remarks**

**4**

**2012 detailed financial performance**

# 2012, healthy performance in a challenging year

---

# In 2012, Ipsen beat sales and profitability objectives


	2012 guidance	2012 actuals
Specialty Care - Drug sales*	~ +10.0%	+11.3% ✓
Primary Care - Drug sales*	~ (15.0%)	(13.2%) ✓
Recurring Adjusted** operating margin	~ 15.0%	16.1% ✓

The above objectives were set at constant currency

**Strong operating performance in light of significant French primary care headwind**


# In 2012, strong specialty care performance, up 11.3%

Drug Sales - FY 2012  
in million euros - % excluding foreign exchange impacts



# A successful franchise-based organization showing accelerating growth

Franchise y-o-y growth at *constant perimeter*



Specialty care up 11.3% with all franchises delivering strong volume growth




# Group sales growth driven by all regions in 2012

## G5 growth hampered by French primary care decline

Group sales growth: **+5.1%**  
(incl. Drug related sales)

At constant currency : **+3.3%**



### ▪ ROW

- Strong volume growth across the region

### ▪ North America

- Continued penetration of Somatuline<sup>®</sup> and Dysport<sup>®</sup> sales to partner
- Sales up 11.5% y-o-y restated to exclude Apokyn<sup>®\*</sup>

### ▪ Other European countries

- Sustained volume growth, in Russia, Poland, the Netherlands and Ukraine

### ▪ European G5

- Strong Specialty care growth more than offset by French primary care and administrative measures in Spain
- **Excluding French primary care, G5 grew 6.9% y-o-y at constant currency**

■ Major Western European countries    □ Other European Countries  
■ North America    ■ Rest of the World

# Growth driven by emerging markets



## Growth

**c.+20%**

- Very successful OTC campaign on Smecta® and Tanakan®
- Very strong performance of Decapeptyl® and Dysport®, market leader



**c.+23%**

- Very strong performance of Dysport® both in therapeutic and aesthetic indications, market leader



**~c.14%<sup>1</sup>**


<sup>1</sup> Performance restated to exclude Etiasa®

- Strong performance negatively impacted by price and volume impact of Etiasa® inventory destruction
- Very strong performance of Decapeptyl®, up ~25%
- Continued penetration of Smecta®

# Focus on Russia


## Ipsen outperforming Russian pharma market

Base 100 comparison Ipsen Russia growth vs. market



## Ipsen Russia showing fast and accelerating growth

Net sales at constant FX rate [Meur]



# In 2012, an outstanding performance in Europe, up 7.6% excluding Primary care France

## Examples



Growth: c.+14%

Supported by very strong performance of Decapeptyl<sup>®</sup> and Somatuline<sup>®</sup>



Growth in Nordic countries: c.+14%

Supported by strong performance of Decapeptyl<sup>®</sup> and Somatuline<sup>®</sup>




Growth: c.+21%

Supported by very strong performance of Somatuline<sup>®</sup> and the successful launch of Hexvix<sup>®</sup>




Poland: c.+33%

Successful market access campaign on Somatuline<sup>®</sup>



# Sales growth in 2012: Ipsen performs well in the pharma and biotech markets



Ipsen FY12 growth at constant currency: +3.3%


# Key clinical development milestones achieved in 2012

	Clinical development phase	Progress	Molecule/Drug
✓	Phase I	Initiated and completed	BN 82451 Huntington Disease
✓	Phase II	Initiated	Tasquinimod 4 POCs <i>(hepato-cellular, ovarian, renal cell and gastric carcinomas)</i>
✓	Phase II	Initiated	Tasquinimod Maintenance post Docetaxel
✓	Phase II	Completed	Dysport® Next Generation Glabellar Lines - Europe
✓	Phase III	Fully recruited	Tasquinimod mCRPC
✓	Phase III	Fully recruited	Dysport® Next Generation CD - Europe
✓	Phase III	Fully recruited	Somatuline® Functioning NET US

Ipsen replenishing early-stage pipeline while executing on phase IIIs

# Ipsen adapting to a challenging environment in French primary care

## French primary care sales down 29.7% in 2012



## French primary care restructuring plan

- >175 positions, mainly commercial (c.2/3 of total French primary care sales force)

- One-off\* restructuring costs accrued in 2012 and mainly cashed out in 2013
- Synergies from the new organization of French primary care commercial operations are expected in 2014

# Exit from hemophilia franchise

## OBI-1 + Milford facility

- Sold to Baxter International
- Deal terms:
  - \$50 million upfront
  - Up to \$135 million in potential additional development and commercial milestones
  - Net sales payments ranging from 12.5% to 17.5% of OBI-1 annual net sales

## IB1001

- Sold to Cangene
- Deal terms:
  - \$5.9 million upfront
  - Up to \$50 million in potential additional commercial milestones
  - Net sales payments ranging from 0% to 25% of IB1001 annual net sales

## FINANCIALS


### Ipsen to receive:

- c.60% of upfront payments
- 80% of all payments up to a present value of \$304 million over and above upfront amounts
- 50% of all proceeds thereafter

- **One-off impairment charge\* of €100m after tax booked in 2012 discontinued operations**
- **All hemophilia-related revenues and costs reallocated to discontinued operations**



# In 2012, transformation progressed with new orientation in French primary care and sale of hemophilia




**Transformation continues...**

# Business and Strategy update

---


# In Q1 2013, specialty care sales grew strongly at 8.0%, while primary care sales were resilient at (1.9%)

Drug Sales - Q1 2013  
in million euros - % excluding foreign exchange impacts



# In Q1, Group sales growth very strong in ROW countries

## G5 growth penalized by tough French and Spanish markets



### ROW

- Strong volume growth across the region, especially in China, Australia, Algeria and Vietnam

### North America

- Continued penetration of Somatuline® and Dysport® sales to partner


### Other European countries

- Mainly driven by Russia, where both specialty and primary care performed strongly

### European G5


- Solid growth in the UK and Germany
- In France, tougher primary care competitive environment and slight decline in specialty care sales<sup>1</sup>
- Significant decline of the Spanish pharmaceutical market

# Good relative performance of Ipsen sales in Q1 2013



Ipsen Q1 13 growth at constant currency: +5.3%

# Business and Strategy update on 2013 milestones



# **A:** Levers to drive franchise and geographical growth

**Uro- Oncology**

**Endocrinology**

**Neurology**

- **New indications/Innovation**
  - **Geographic expansion**
  - **Life cycle management**
  - **Partnerships**

**Leverage franchises through external acquisitions/in-licensing**

# B: US operations to drive Group profitability

By end of 2013

- Increlex® shortage expected in Q2
- Checkpoint: Assessment of transformation progress

Time

2015/2016  
Leveraging structure with new indications

FY 2012

- Dysport® still challenging
- Endocrinology Business Unit profitable

2014/2015

- Expected breakeven\*

**Increlex® shortage expected in Q2 2013 in the US<sup>(1)</sup>**  
**The US subsidiary was instructed to compensate the full impact of the shortage at the EBIT level**



# C: Critical clinical data expected in 2013/2014

Clinical development phase	Expected data	Expected timing	Molecule/Drug
Phase III	Topline results	H2 2013	Dysport® Next Generation – CD – Europe
Phase III	Topline results	Q4 2013	Somatuline® Functioning NET US
Phase III	Topline results	Q4 2013	Somatuline® Non Functioning NET WW
Phase III	Topline results	H1 2014	Dysport® AUL Spasticity
Phase III	PFS and OS data (preliminary analysis)	2014	Tasquinimod in mCRPC


# C: Ipsen and Active Biotech update the analysis plan for tasquinimod to maximize the chances of approval by regulatory bodies

Tasquinimod is in Phase III in patients with metastatic castrate-resistant prostate cancer who have not yet received chemotherapy

	Clinical development phase	Planned analyses	Planned dates
Initial calendar	Phase III	Progression-free survival	Q4 2013
New calendar	Phase III	Progression-free survival and <u>overall survival</u>	2014

Given the evolution of the regulatory and medical environment in the field of prostate cancer, Ipsen and Active Biotech decided to update the analysis plan for the 10TASQ10 trial to maximize the chances of approval for tasquinimod by regulatory bodies and the granting of an attractive price and to increase the commercial potential of the product

# C: Tasquinimod, a unique pleiotropic mechanism of action in CRPC



1

Isaacs JT et al. Prostate 2006;66:1768-78  
 Olsson A et al. Mol Cancer 2010;9:107  
 Isaacs JT, Expert Opin Investig Drugs (2010) 19(10):1235-1243

2

Källberg et al. PLoS ONE in press (2012)  
 Hermani et al. Clin Cancer Res (2005) 11, 14, 5146-52  
 Cheng P et al., J Exp Med. (2008) 29;205(10):2235-49.  
 Hiratsuka S et al., Nat Cell Biol. (2006) 8(12):1369-75.  
 Rafii S & Lyden D, Nat Cell Biol. (2006) 8(12):1321-3.  
 Sinha et al, J of immunology 2008, 181:4666-4675.

3

Jennbacken K et al. Prostate 2011

# **D**: Ipsen gears up to accelerate strategy execution with the appointment of Christel Bories as Deputy CEO



A true expertise and significant experience  
in company transformation

External view on the company  
and the industry

Shares Ipsen values

Motivation, curiosity, open-mindedness

# 2013 Financial objectives & closing remarks

---

# 2013 financial objectives

Specialty care – Drug sales

Growth of +6.0% to +8.0%, year-on-year

- *Driven by continued and solid volume growth, in a context of increased pricing pressure and uncertainty on Increlex<sup>®</sup> supply as of today*

Primary care – Drug sales

Decline of -8.0% to -6.0%, year-on-year

- *French primary care to remain under pressure*

Recurring Adjusted\* operating margin

Around 16.0% of sales

- *The Group expects a continued decrease of French primary care margin in 2013. Synergies from the new organization of French primary care commercial operations are expected to materialize in 2014*

The above objectives are set at constant currency and perimeter

# 2013, accelerating the execution of our strategy

2011



Definition and implementation of new strategy

2012



Robust performance in a challenging environment

2013



Accelerating the execution of our strategy  
to achieve our 2020 ambitions

# 2012 detailed financial performance

---



# 2012: Strong operating performance in light of French primary care headwind

Dynamic and sustained specialty care sales growth of +11.3%<sup>1</sup>  
Strong French primary care sales decrease (-29.7%)

Reported Operating Income impacted by new organization of French primary care commercial operations


Recurring Adjusted<sup>2</sup> Operating margin of 16.1%<sup>3</sup>, strong performance in light of French primary care headwind

Net loss of (€29.0m), impacted by the Group's decision to exit hemophilia

Recurring adjusted<sup>2</sup> EPS of € 1.74 versus 1.85<sup>(\*)</sup> in 2011

Strong cash flow generated by operating activities of €165.0m


# Other Revenues(\*)




- **Royalties Received**  
Increased royalties from the Group's partners
- **Milestones**  
Stemming from the Group's main partnerships (Medicis, Galderma, Menarini...)
- **Other revenues**  
Increased revenues from the Group's co-promotion and co-marketing agreements in France as well as promotion of Hexvix® in some countries

# Main P&L(\*) items: above operating income


## COGS (€m)




## R&D (€m)



## Sales & Marketing costs (€m)



## G&A (€m)




(\*) 2011 figures have been restated to provide comparative information between 2011 and 2012 – <sup>(1)</sup> in % of sales

# From reported to Recurring adjusted Operating Income(\*)

2011

In million euros




+ 58.3%  
As reported

-0.7%  
Recurring adjusted

2012


In million euros




(\*) 2011 figures have been restated to provide comparative information between 2011 and 2012

# Main P&L(\*) items : Below operating income


Financial Result (€m)




Effective tax rate



Net income from discontinued operations (€m)



Consolidated result (€m)



# Balance sheet evolution

## ASSETS

	2011	2012
Goodwill	299.5	298.2
Investments in associates	0.0	0.0
Property, plant and equipment	271.7	281.8
Other intangible assets	135.6	129.2
Other non current assets	293.8	245.6
<b>Non-current assets</b>	<b>1,000.6</b>	<b>954.7</b>
<b>Current assets</b>	<b>632.8</b>	<b>606.3</b>
<i>Incl. Cash and cash equivalents</i>	145.0	113.6
Non current assets and assets of disposal groups classified as held for sale	-	-
<b>Total Assets</b>	<b>1,633.4</b>	<b>1,561.1</b>
<b>Closing cash position</b>	<b>144.8</b>	<b>113.3</b>

## LIABILITIES

	2011	2012
Capital and reserves	1,012.8	924.2
Minority interest	2.6	2.0
<b>Total equity</b>	<b>1,015.4</b>	<b>926.3</b>
Other financial liabilities	16.6	15.9
Other non current liabilities	231.0	182.0
Other current liabilities	341.9	394.3
Provision and Short-term debt	28.5	70.2
Liabilities included in disposal groups classified as held for sale	0.0	0.5
<b>Total Liabilities</b>	<b>1,633.4</b>	<b>1,561.1</b>

# Cash flow generation<sup>(\*)</sup>

*In million euros*

	2011	2012
<b>Cash flow from operating act. before changes in working cap.</b>	<b>189.5</b>	<b>175.3</b>
Net change in other operating assets & liabilities	(20.7)	(10.3)
<b>Net cash flow generated by operating activities</b>	<b>168.8</b>	<b>165.0</b>
Purchase of tangible and intangible assets	(95.2)	(76.5)
Sale price of shares	-	13.9
Cash flow from investing activities – other	(0.7)	(0.5)
Others	0.2	(1.5)
<b>Net cash flow used in investing activities</b>	<b>(95.7)</b>	<b>(64.8)</b>
Settlement of It loans	(0.3)	(0.3)
Dividends paid	(66.5)	(67.5)
DIP financing	0.0	(7.2)
Others	1.6	1.8
<b>Net cash used in financing activities</b>	<b>(65.2)</b>	<b>(73.2)</b>
Impact of discontinued operations	(40.8)	(56.2)
<b>Change in cash and cash equivalents</b>	<b>(32.9)</b>	<b>(29.2)</b>
Effects of exchange rate changes	(0.2)	(2.3)
<b>Closing cash position</b>	<b>144.8</b>	<b>113.3</b>

**Continued strong operating cash flow generation in 2012**

Thank You

---